JP2019504623A - 免疫原性剤としてのストレプトコッカス・ウベリス抽出物 - Google Patents
免疫原性剤としてのストレプトコッカス・ウベリス抽出物 Download PDFInfo
- Publication number
- JP2019504623A JP2019504623A JP2018538841A JP2018538841A JP2019504623A JP 2019504623 A JP2019504623 A JP 2019504623A JP 2018538841 A JP2018538841 A JP 2018538841A JP 2018538841 A JP2018538841 A JP 2018538841A JP 2019504623 A JP2019504623 A JP 2019504623A
- Authority
- JP
- Japan
- Prior art keywords
- mastitis
- biofilm
- vaccine
- uberis
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 title claims abstract description 107
- 239000000284 extract Substances 0.000 title claims abstract description 15
- 241000194054 Streptococcus uberis Species 0.000 title abstract description 18
- 229940115922 streptococcus uberis Drugs 0.000 title abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 122
- 208000015181 infectious disease Diseases 0.000 claims abstract description 112
- 208000004396 mastitis Diseases 0.000 claims abstract description 111
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 102
- 230000002265 prevention Effects 0.000 claims abstract description 87
- 241000194017 Streptococcus Species 0.000 claims abstract description 59
- 239000002253 acid Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 50
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 238000002255 vaccination Methods 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 13
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 12
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 10
- 229920002307 Dextran Polymers 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 239000012298 atmosphere Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims description 4
- 229920001503 Glucan Polymers 0.000 claims description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 229920000392 Zymosan Polymers 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- 229940031439 squalene Drugs 0.000 claims description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 38
- 241000283690 Bos taurus Species 0.000 description 31
- 235000013336 milk Nutrition 0.000 description 25
- 239000008267 milk Substances 0.000 description 25
- 210000004080 milk Anatomy 0.000 description 25
- 235000013365 dairy product Nutrition 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 208000031462 Bovine Mastitis Diseases 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 210000005075 mammary gland Anatomy 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000001974 tryptic soy broth Substances 0.000 description 11
- 108010050327 trypticase-soy broth Proteins 0.000 description 11
- 229940041514 candida albicans extract Drugs 0.000 description 10
- 238000013167 light transmission aggregometry Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000012138 yeast extract Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 230000032770 biofilm formation Effects 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 241001138504 Mycoplasma bovis Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229940030998 streptococcus agalactiae Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000194022 Streptococcus sp. Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000878103 Bacillus subtilis (strain 168) Iron(3+)-hydroxamate-binding protein FhuD Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194056 Streptococcus iniae Species 0.000 description 1
- 241000194055 Streptococcus parauberis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical group OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical group 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
・感染後24時間の組織のCFU/gの減少(図2)、及び
・感染後の罹患腺の感受性の低下(図3)
が観察されたため、結果は、S.ウベリスによって引き起こされる感染症を予防するための本発明の免疫原性剤の有効性を明らかに示した。
・感染2日後の温度低下(図4)、
・乳中のCFU/mlの減少(図5)、
・対照群と比較した乳産生量の増加(図6)、及び
・研究終了時の乳中の体細胞数(SC/ml)の減少(図7)
が観察されたことから、結果は、S.ウベリスによって引き起こされる感染症を予防するための本発明の免疫原性剤の有効性を明らかに示した。
Claims (22)
- a)バイオフィルムを得るために、バイオフィルム産生S.ウベリス株をインキュベートする工程と、
b)前記工程a)で得られた前記バイオフィルムに熱的加熱処理を施す工程と、
を含むことを特徴とする、免疫原性剤の調製方法。 - 前記インキュベーションが1%〜10%の二酸化炭素を含む雰囲気中で行われることを特徴とする、請求項1に記載の方法。
- 前記工程b)において、前記熱処理が80℃〜130℃の温度で行われることを特徴とする、請求項1又は2に記載の方法。
- 前記工程b)において、前記熱処理が5〜75分の期間行われることを特徴とする、請求項1〜3のいずれか1項に記載の方法。
- 前記工程a)の後、かつ前記工程b)の前に、培地から前記バイオフィルムを回収する追加の工程を含むことを特徴とする、請求項1〜4のいずれか1項に記載の方法。
- 前記工程b)の前記熱処理後に得られた不溶性画分を廃棄し、可溶性抽出物を保存する工程を含むことを特徴とする、請求項1〜5のいずれか1項に記載の方法。
- バイオフィルム産生S.ウベリス菌株の培養物由来の熱的加熱処理されたバイオフィルムを含む、免疫原性剤。
- ストレプトコッカス種によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療に使用するための、請求項7に記載の免疫原性剤。
- 前記ストレプトコッカス種によって引き起こされる乳腺炎及び/又は感染症の予防に使用するための、請求項8に記載の免疫原性剤。
- 免疫学的に有効な量の請求項7に記載の免疫原性剤を含む、ワクチン。
- 薬学的に許容されるビヒクル及び/又は薬学的に許容されるアジュバントを更に含むことを特徴とする、請求項10に記載のワクチン。
- 水酸化アルミニウム、リン酸アルミニウム、酸化アルミニウム、ムラミルジペプチド、ビタミンE、スクワラン、スクワレン、チョウセンニンジン、ザイモサン、グルカン、ジメチルアミノエチル−デキストラン、デキストラン、非イオン性ブロックポリマー、モノホスホリルリピドA、サポニン、及びこれらの混合物から選択されるアジュバントを含むことを特徴とする、請求項11に記載のワクチン。
- モノホスホリルリピドAを含むことを特徴とする、請求項12に記載のワクチン。
- 皮内、皮下、筋肉内、腹腔内、静脈内、又は乳房的経路によって投与されることを特徴とする、請求項10〜13のいずれか1項に記載のワクチン。
- 2回以上投与されることを特徴とする、請求項10〜14のいずれか1項に記載のワクチン。
- ストレプトコッカス種によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療に使用するための、請求項10〜15のいずれか1項に記載のワクチン。
- バイオフィルム産生細菌によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療に使用するための、請求項10〜15のいずれか1項に記載のワクチン。
- 免疫学的に有効な量の請求項7に記載の免疫原性剤又は請求項10〜13のいずれか1項に記載のワクチンを含む容器を含むことを特徴とする、ワクチン接種キット。
- ストレプトコッカス種によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療に使用するためのタイコ酸を含む、医薬組成物。
- バイオフィルム産生細菌によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療に使用するためのタイコ酸を含む、医薬組成物。
- ストレプトコッカス種によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療におけるワクチンとして使用するためのタイコ酸を含む、医薬組成物。
- バイオフィルム産生細菌によって引き起こされる乳腺炎及び/又は感染症の予防及び/又は治療におけるワクチンとして使用するためのタイコ酸を含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382060 | 2016-02-15 | ||
EP16382060.8 | 2016-02-15 | ||
PCT/EP2017/053306 WO2017140683A2 (en) | 2016-02-15 | 2017-02-14 | Streptococcus uberis extract as an immunogenic agent |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019504623A true JP2019504623A (ja) | 2019-02-21 |
JP2019504623A5 JP2019504623A5 (ja) | 2020-03-26 |
JP6839199B2 JP6839199B2 (ja) | 2021-03-03 |
Family
ID=55646514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018538841A Active JP6839199B2 (ja) | 2016-02-15 | 2017-02-14 | 免疫原性剤としてのストレプトコッカス・ウベリス抽出物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10946085B2 (ja) |
EP (1) | EP3417049B1 (ja) |
JP (1) | JP6839199B2 (ja) |
KR (1) | KR20180108619A (ja) |
AU (1) | AU2017220528A1 (ja) |
BR (1) | BR112018015255A2 (ja) |
CA (1) | CA3012419A1 (ja) |
ES (1) | ES2960326T3 (ja) |
MX (1) | MX2018009048A (ja) |
PL (1) | PL3417049T3 (ja) |
WO (1) | WO2017140683A2 (ja) |
ZA (1) | ZA201805039B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048111A1 (ja) | 2021-09-21 | 2023-03-30 | 国立研究開発法人 農業・食品産業技術総合研究機構 | 無莢膜株を抗原として含むワクチン |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60243024A (ja) * | 1983-12-29 | 1985-12-03 | Kitasato Inst:The | ストレプトコツカス・サンギス感染症予防用ワクチン,診断用抗原および抗体 |
JPH05148157A (ja) * | 1991-01-28 | 1993-06-15 | Merck & Co Inc | 肺炎連鎖球菌からの多糖抗原 |
JP2009514788A (ja) * | 2005-07-20 | 2009-04-09 | ザ・スクリプス・リサーチ・インステイチユート | 哺乳動物対象においてグラム陽性細菌感染を治療するための組成物及び方法 |
US20110028407A1 (en) * | 2007-02-09 | 2011-02-03 | Jutila Mark A | Enhancement of innate resistance to infection |
WO2012116447A1 (en) * | 2011-03-03 | 2012-09-07 | The Governors Of The University Of Alberta | Use of bacterial endotoxins and lipoteichoic acids to improve postpartal health and productivity of dairy cows and their newborns |
JP2012530785A (ja) * | 2009-06-22 | 2012-12-06 | ワイス・エルエルシー | 組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法 |
JP2014516950A (ja) * | 2011-05-12 | 2014-07-17 | インターベット インターナショナル ベー. フェー. | 乳腺炎の治療 |
JP2014523873A (ja) * | 2011-06-19 | 2014-09-18 | ヴァクシン プロプライエトリー リミテッド | 強化された免疫賦活化剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ308991A (en) | 1995-06-08 | 1999-04-29 | Univ Saskatchewan | Camp factor of streptococcus uberis |
CA2411927C (en) | 2000-06-12 | 2012-08-07 | University Of Saskatchewan | Immunization of dairy cattle with gapc protein against streptococcus infection |
SI2068918T1 (sl) | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
GB0818231D0 (en) | 2008-10-06 | 2008-11-12 | Univ Nottingham | Composition |
AU2014321369B2 (en) | 2013-09-19 | 2020-04-16 | Zoetis Services Llc | Oil-based adjuvants |
-
2017
- 2017-02-14 US US16/075,092 patent/US10946085B2/en active Active
- 2017-02-14 KR KR1020187021575A patent/KR20180108619A/ko unknown
- 2017-02-14 PL PL17704038.3T patent/PL3417049T3/pl unknown
- 2017-02-14 MX MX2018009048A patent/MX2018009048A/es unknown
- 2017-02-14 AU AU2017220528A patent/AU2017220528A1/en not_active Abandoned
- 2017-02-14 EP EP17704038.3A patent/EP3417049B1/en active Active
- 2017-02-14 ES ES17704038T patent/ES2960326T3/es active Active
- 2017-02-14 JP JP2018538841A patent/JP6839199B2/ja active Active
- 2017-02-14 CA CA3012419A patent/CA3012419A1/en active Pending
- 2017-02-14 BR BR112018015255-2A patent/BR112018015255A2/pt unknown
- 2017-02-14 WO PCT/EP2017/053306 patent/WO2017140683A2/en active Application Filing
-
2018
- 2018-07-26 ZA ZA2018/05039A patent/ZA201805039B/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60243024A (ja) * | 1983-12-29 | 1985-12-03 | Kitasato Inst:The | ストレプトコツカス・サンギス感染症予防用ワクチン,診断用抗原および抗体 |
JPH05148157A (ja) * | 1991-01-28 | 1993-06-15 | Merck & Co Inc | 肺炎連鎖球菌からの多糖抗原 |
JP2009514788A (ja) * | 2005-07-20 | 2009-04-09 | ザ・スクリプス・リサーチ・インステイチユート | 哺乳動物対象においてグラム陽性細菌感染を治療するための組成物及び方法 |
US20110028407A1 (en) * | 2007-02-09 | 2011-02-03 | Jutila Mark A | Enhancement of innate resistance to infection |
JP2012530785A (ja) * | 2009-06-22 | 2012-12-06 | ワイス・エルエルシー | 組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法 |
WO2012116447A1 (en) * | 2011-03-03 | 2012-09-07 | The Governors Of The University Of Alberta | Use of bacterial endotoxins and lipoteichoic acids to improve postpartal health and productivity of dairy cows and their newborns |
JP2014516950A (ja) * | 2011-05-12 | 2014-07-17 | インターベット インターナショナル ベー. フェー. | 乳腺炎の治療 |
JP2014523873A (ja) * | 2011-06-19 | 2014-09-18 | ヴァクシン プロプライエトリー リミテッド | 強化された免疫賦活化剤 |
Non-Patent Citations (3)
Title |
---|
FINCH,J.M. ET AL: "Local vaccination with killed Streptococcus uberis protects the vovine mammary gland against experim", INFECTION AND IMMUNITY, vol. 62(9), JPN6020041190, September 1994 (1994-09-01), pages 3599 - 3603, ISSN: 0004377369 * |
GUENTHER J. ET AL: "Streptococcus uberis strains isolated from the bovine mammary gland evade immune recognition by mamm", VETERINARY RESEARCH, vol. 47(13), JPN6020041192, 7 January 2016 (2016-01-07), pages 1 - 14, ISSN: 0004377370 * |
MOOR, G.E.: "Biofilm Production by Streptococcus uberis Associated with Intramammary Infections", TRACE: TENNESSEE RESEARCH AND CREATIVE EXCHANGE, JPN6020041194, 2009, pages 1 - 14, ISSN: 0004425882 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017140683A3 (en) | 2017-10-12 |
US10946085B2 (en) | 2021-03-16 |
PL3417049T3 (pl) | 2024-02-19 |
MX2018009048A (es) | 2019-03-28 |
EP3417049A2 (en) | 2018-12-26 |
ZA201805039B (en) | 2020-05-27 |
BR112018015255A2 (pt) | 2018-12-18 |
US20190038736A1 (en) | 2019-02-07 |
EP3417049B1 (en) | 2023-08-16 |
CA3012419A1 (en) | 2017-08-24 |
WO2017140683A2 (en) | 2017-08-24 |
KR20180108619A (ko) | 2018-10-04 |
AU2017220528A1 (en) | 2018-08-09 |
ES2960326T3 (es) | 2024-03-04 |
JP6839199B2 (ja) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nordhaug et al. | A field trial with an experimental vaccine against Staphylococcus aureus mastitis in cattle. 1. Clinical parameters | |
KR100355961B1 (ko) | 그람염색음성구균의전체막으로부터지방과당류-결핍된외부막제조방법 | |
JP2019068864A (ja) | 過剰ブレブ形成Shigella株 | |
Eko et al. | Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili | |
US8778655B2 (en) | Modified gram-negative bacteria for use as vaccines | |
US10434168B2 (en) | Attenuated bovine coronavirus and related vaccines | |
JP2002519388A (ja) | ヘモフィルス・パラスイスのワクチン及び診断薬 | |
Angelos | Moraxella | |
NO175735B (no) | Fremgangsmåte ved fremstilling av Pasteurella-vaksine | |
Mukhopadhaya et al. | Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition | |
Riottot et al. | Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations | |
JP5847713B2 (ja) | 豚胸膜肺炎に対するワクチン及び当該ワクチンの取得方法 | |
JP6839199B2 (ja) | 免疫原性剤としてのストレプトコッカス・ウベリス抽出物 | |
WO1993010815A1 (en) | Non-capsulated mutants of bacteria useful as vaccines | |
JP2023517684A (ja) | ストレプトコッカス・スイス血清型9、配列型16に対する防御のためのワクチン | |
US11045536B2 (en) | Vaccine | |
Rioux et al. | Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice | |
JP2023503058A (ja) | ヘモフィルス・パラスイスに対する新規ワクチン | |
KR100258772B1 (ko) | 돼지의 흉막폐염 백신 조성물 | |
KR101599281B1 (ko) | 폐렴연쇄상구균 유래 막소포체를 포함하는 폐렴연쇄상구균 백신 조성물 | |
PT103450A (pt) | Vacina contra streptococcus agalactiae usando como antigénio alvo a proteína gliceraldeído-3-fosfato desidrogenase (gapdh) produzida pela bactéria, na sua forma nativa ou recombinante | |
RU2601158C1 (ru) | ШТАММЫ ВИДА Streptococcus pneumoniae (ВАРИАНТЫ) И СПОСОБ ПОЛУЧЕНИЯ ИЗ НИХ ПРОТЕКТИВНОЙ БЕЛОКСОДЕРЖАЩЕЙ ФРАКЦИИ, ОБЛАДАЮЩЕЙ ВНУТРИВИДОВОЙ ИММУНОГЕННОЙ АКТИВНОСТЬЮ | |
TW202214294A (zh) | 具有hyaC及nanP缺失之新穎多殺性巴斯德氏菌株及疫苗 | |
JPH0645554B2 (ja) | クレブシェラ莢膜多糖類ワクチンおよびその製法 | |
Costa et al. | Evaluation of the humoral and cellular immune response to different antigens of Corynebacterium pseudotuberculosis in Canindé goats and their potential protection against caseous lymphadenitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200213 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200213 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6839199 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |